After Acquisition, Agilent Plans to Combine Stratagene’ Kits and Software with its Own | GenomeWeb
Six months after buying Stratagene for $246 million, Agilent this week shed more light on its plans for the business, which has functioned as an autonomous division since June.
 
Nick Roelofs, vice president of Agilent’s Life Sciences Solutions Unit, said the company intends to maintain Stratagene’s brand, organization, and platform-independent product line of reagents and bioinformatics software.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.